Understanding how a protein affects aggressive prostate cancer
Nuclear Neuropilin2: a novel molecular mediator for aggressive Prostate Cancer
['FUNDING_R01'] · VIRGINIA COMMONWEALTH UNIVERSITY · NIH-10819171
This study is looking at how a protein called Neuropilin-2 affects the growth of aggressive prostate cancer, with the goal of helping doctors better predict which patients might face more serious disease and finding new treatment options for those at higher risk.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | VIRGINIA COMMONWEALTH UNIVERSITY (nih funded) |
| Locations | 1 site (RICHMOND, UNITED STATES) |
| Trial ID | NIH-10819171 on ClinicalTrials.gov |
What this research studies
This research investigates the role of Neuropilin-2 (NRP2) in the progression of aggressive prostate cancer. By examining how NRP2 influences gene transcription related to cancer promotion, the study aims to develop a molecular classification system that can better predict which patients are at risk for aggressive disease. The approach includes analyzing the transport mechanisms of NRP2 within cells to understand its function in cancer progression. Ultimately, this research seeks to identify potential therapeutic targets for patients with high-risk prostate cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with localized prostate cancer who are at risk of developing aggressive disease.
Not a fit: Patients with indolent prostate cancer who are not at risk of progression may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved methods for identifying and treating aggressive prostate cancer, potentially reducing the risk of metastasis.
How similar studies have performed: Previous research has shown promise in targeting molecular mediators in cancer, suggesting that this approach could yield significant insights.
Where this research is happening
RICHMOND, UNITED STATES
- VIRGINIA COMMONWEALTH UNIVERSITY — RICHMOND, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DATTA, KAUSTUBH — VIRGINIA COMMONWEALTH UNIVERSITY
- Study coordinator: DATTA, KAUSTUBH
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.